A2 Biotherapeutics, Inc. Their revolutionary Tmod™ technology, invented by experienced scientists, forms the backbone of their broad pipeline of solid tumor cell therapies. A2 Bio draws on decades of experience in drug discovery and leverages quantitative methods to drive innovation in the field of cell therapy.

By exploiting the loss of genetic material commonly observed in tumors, their technology offers a first-mover advantage in the treatment of solid tumors. Driven by a commitment to rigorous science and the urgent need to provide effective cell therapies, A2 Bio is led by an experienced leadership team. Supported by a world-class scientific advisory board and powered by dedicated scientists and staff, they are uniquely positioned to deliver a wide range of T cell therapies to cancer patients.

Protecting their technology and products with a comprehensive set of patent filings, A2 Bio's mission is to transform cancer treatment for the better. With a timeline marked by significant achievements, including successful financing campaigns, establishment of research and manufacturing facilities, and collaborations with industry leaders, A2 Bio continues to make strides in advancing their innovative therapies. Their dedication to science, combined with their state-of-the-art infrastructure, positions them as a leading force in the field of T cell therapies